Our results overall strengthen the overwhelming necessity of cost-effective and practical methods for EGFR mutation detailed characterization[7] for NSCLC patient management, even when dealing with small amount of tumoral tissue. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.